Dr Dumbrava is a Medical Oncologist and Assistant Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center and Director for MD Anderson Cancer Network Research for Investigational Cancer Therapeutics/Phase 1. Dr Dumbrava completed her medical oncology training at Gustave Roussy Cancer Center in Villejuif, France, followed by a Master of Science Degree from Paris-South University and a postdoctoral fellowship in the Department of Translational Molecular Pathology at The University of Texas MD Anderson Cancer Center. She completed two years of Clinical Fellowship in the Investigational Cancer Therapeutics Department, where she was elected Chief Fellow and during which she did a clinical research rotation at NCI/CTEP. She joined the Department of Investigational Cancer Therapeutics since August 2018 as an Assistant Professor. She is also member of the Brain Metastasis Clinic. Dr Dumbrava was the FY19 K12 Paul Calabresi Scholar Award and FY21 Gateway Foundation for Cancer Research Award recipient. Dr Dumbrava is overseeing the Inpatient Service and leading the HER2 Working Group in the Investigational Cancer Therapeutics Department at The University of Texas MD Anderson Cancer Center and she also an active member in the Immunotherapy and Cellular Therapies Working Group. Her main area of research lies in targeting p53 and HER2 and developing cellular therapies for solid tumors and genomically matched combination therapies and personalized immunotherapy clinical trials.